Please login to the form below

Not currently logged in
Email:
Password:

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

Roche’s Ocrevus boasts positive long-term data in MS

Roche’s Ocrevus boasts positive long-term data in MS

Following two years of using Ocrevus twice-yearly, 75% of relapsing-remitting multiple sclerosis (RRMS) patients had no evidence of disease activity. ... Ocrevus. Patients treated with Ocrevus also experienced an improvement in the majority of their

Latest news

More from news
Approximately 20 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics